Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC


Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Charles M. Rudin, MD, PhD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer (ES-SCLC).

In June 2019, the FDA approved pembrolizumab for the treatment of patients with metastatic SCLC who experience disease progression on or after platinum-based chemotherapy and at least 1 prior line of therapy.

KEYNOTE-604 evaluated whether pembrolizumab plus etoposide and platinum induced an improved response compared with placebo as first-line treatment for patients with ES-SCLC, says Rudin.

Findings from the study showed that the PD-1 inhibitor plus chemotherapy significantly improved progression-free survival compared with placebo.

Related Videos
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic